DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TROSPIUM CHLORIDE

« Back to Dashboard

Clinical Trials for Trospium Chloride

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00465959	Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease	Completed	Alkermes, Inc.	Phase 1/Phase 2	To assess the effect of a single dose of TrIP on pulmonary function in patients with COPD
NCT00465959	Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease	Completed	Endo Pharmaceuticals	Phase 1/Phase 2	To assess the effect of a single dose of TrIP on pulmonary function in patients with COPD
NCT00800462	Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity	Completed	Ontario Neurotrauma Foundation	Phase 4	This is a phase IV, double-blind, multicenter, randomized trial evaluating the efficacy and safety of two M3 receptors antagonists (Trospium Chloride and Darifenacin Hydrobromide) with one standard drug (Oxybutynin Chloride) for treatment of overactive bladder in individuals with spinal cord injury.
NCT00800462	Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity	Completed	Toronto Rehabilitation Institute	Phase 4	This is a phase IV, double-blind, multicenter, randomized trial evaluating the efficacy and safety of two M3 receptors antagonists (Trospium Chloride and Darifenacin Hydrobromide) with one standard drug (Oxybutynin Chloride) for treatment of overactive bladder in individuals with spinal cord injury.
NCT00863551	Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial	Completed	Allergan	Phase 4	This study evaluates the penetration through the blood-brain-barrier of trospium chloride at plasma steady state (Day 10) in elderly subjects with overactive bladder symptoms. Trospium levels in cerebrospinal fluid (CSF) and peak and trough plasma levels will be measured. Baseline and day 10 post-dose neurocognitive testing will be compared using a reliable change index to assess if any study subject shows evidence of a clinically and statistically significant change in memory.

Clinical Trial Conditions for Trospium Chloride

Condition Name

Condition Name for Trospium Chloride
Intervention	Trials
Overactive Bladder	4
Intestinal Obstruction	2
Cognitive Function	1
Neurogenic Detrusor Overactivity	1

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Trospium Chloride
Intervention	Trials
Urinary Bladder, Overactive	5
Intestinal Obstruction	2
Ureteral Calculi	1
Lung Diseases	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Trospium Chloride

Trials by Country

Trials by Country for Trospium Chloride
Location	Trials
United States	8
Germany	2
Canada	2

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Trospium Chloride
Location	Trials
California	3
Utah	1
Arizona	1
South Carolina	1
Ohio	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Trospium Chloride

Clinical Trial Phase

Clinical Trial Phase for Trospium Chloride
Clinical Trial Phase	Trials
Phase 4	6
Phase 1/Phase 2	1
Phase 1	4

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Trospium Chloride
Clinical Trial Phase	Trials
Completed	10
Active, not recruiting	1
Not yet recruiting	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Trospium Chloride

Sponsor Name

Sponsor Name for Trospium Chloride
Sponsor	Trials
Allergan	5
University Medicine Greifswald	2
University of North Carolina, Chapel Hill	1

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Trospium Chloride
Sponsor	Trials
Industry	8
Other	8

Export unavailable in trial.
Subscribe for complete access.